what planet are you currently living on ? Uranus ? go back to hibernating under your clam shell
Hardly a miss. Second half of year will push this stock up nicely. ALXN had a very good Q and an upbeat conference call. The base biz continues to grow very well & the pipeline continues to improve. ALXN remains one the fastest growing large cap names with revenue & earnings upside. With topline growth of 20% over the next couple of years & 30% EPS growth the 25X PE on current 2016 earnings looks good to me.
SRPT has been a mess for the last year. Yes the CEO has been a disaster in not following FDA protocol but this inexperienced board was never value-add in the company's development. Sadly emotions & bad decision making ran rampant. Why anyone would invest in a bad company not following the FDA process is beyond me.
Not even close---read into it anyway you want. Clearly you weren't in the meeting with management nor heard any of the Q&A. Diplomatic research note.
Clearly you were not in the meeting nor heard any of the Q&A. Peel the onion back on ACAD----not all is or has been going well. The new CEO is not at fault but the prior clowns sure did not run ACAD professionally at all---with more fallout likely to come. Sad.
You buy a stock off of "Stock Gumshoe" ???????? Unless you have lots of money to lose maybe get professional advice.
You ARE a newbie !! Maybe stay with mutual funds or ETFs. IBB may a good way for you to invest in biotechs. Companies like MEIP are likely way beyond your pay grade----you don't know management, the sector, the science. That stacks the odds against you big time.
More often than not you don't the access or the ability to handicap the information.
are you for real ? I bought AMR in bankruptcy and it's now $ 54.MEIP does not resemble AAL other than people guessing & losing $$.
VZ chose not to take CSCO $1 billion vendor financing but rather stay with incumbent 100G vendor CIEN on equal++ footing for CIEN. That bodes well for CIEN where there was a market concern that they would get a minority share of the contract with CSCO buying their way into the order. Fortunately VZ is looking at performance which tells us what they think of CIEN (+++).